Gland Pharma Ltd Analyst Rating
based on 12 analysts
41.67%
Buy
8.33%
Hold
50.00%
Sell
Based on 12 analysts offering long term price targets for Gland Pharma Ltd. An average target of ₹1813.25
Source: S&P Global Market Intelligence
Gland Pharma Ltd Share analysis
Gland Pharma Ltd price forecast by 12 analysts
Downside of
High
₹3120
Target
₹1813.25
Low
₹1214
Gland Pharma Ltd target price ₹1813.25, a slight downside of -0.27% compared to current price of ₹1764.55. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Gland Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:21.72%
Forecast
Actual
Including amortisation and stock based compensations
Gland Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:39.68%
Forecast
Actual
Source: S&P Global Market Intelligence
Gland Pharma Ltd Performance
Day's Low
Day's High
₹1,750₹1,831.952 Week's Low
52 Week's High
₹1,585.7₹2,220.95
| Returns % | |
| 1 Month Return | + 8.15 % |
| 3 Month Return | -10.79 % |
| 1 Year Return | + 11.07 % |
| Market Stats | |
| Previous Close | ₹1,818.10 |
| Open | ₹1,821.70 |
| Volume | 87.56K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹29,953.51Cr |
Gland Pharma Ltd Key Statistics
| P/E Ratio | 43.3 |
| PEG Ratio | -98.41 |
| Market Cap | ₹29,953.51 Cr |
| P/B Ratio | 3.37 |
| EPS | 46.9 |
| Dividend Yield | 1.09 |
| Sector | Pharmaceuticals |
| ROE | 12.31 |
Gland Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹29,953.51 Cr | -0.02% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| HOLD | ₹1,56,625.13 Cr | 50.55% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,06,661.37 Cr | 51.12% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹41,864.92 Cr | 7.17% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| BUY | ₹1,25,403.42 Cr | 49.34% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Gland Pharma Ltd Mutual Fund Holdings
About Gland Pharma Ltd
Gland Pharma's operations include the development, manufacture, and marketing of a wide range of injectable drugs and active pharmaceutical ingredients. The company's product portfolio includes antibiotics, anti-emetics, anti-diabetics, anti-epileptics, and other therapeutic categories. Its top products include cephalosporins, penicillins, and other injectable antibiotics.
Gland Pharma is well known for its popular brands, such as Cephalosporin, Penicillin, and Amikacin. These brands have been widely used in hospitals and clinics across India, as well as in other countries. In addition, the company has developed and launched a wide range of generic and branded injectables, including Cefazolin, Cefuroxime, and Amikacin.
Share Price: ₹1764.55 per share as on 12 Nov, 2024 04:01 PM
Market Capitalisation: ₹29,953.51Cr as of today
Revenue: ₹1,405.83Cr as on September 2024 (Q3 24)
Net Profit: ₹163.53Cr as on September 2024 (Q3 24)
Listing date: 20 Nov, 2020
Chairperson Name: Yiu Kwan Stanley Lau
| Organisation | Gland Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Gland Pharma Ltd
Gland Pharma Stock Rises Despite Profit Decline - 09 Nov, 2024
Gland Pharma shares surged over 10% this week following Q2 results, reporting a profit of Rs 163.53 crore, slightly above expectations, despite a 16% decline from last year due to rising raw material costs.
Motilal Oswal Recommends Buy on Gland Pharma - 07 Nov, 2024
Motilal Oswal Securities has a buy rating on Gland Pharma with a target price of Rs 1,970. The company is expected to recover from earnings decline, projecting a 20% CAGR over FY25-27, driven by increased product volumes and new product commercialization.
Gland Pharma Stock Surges Despite Weak Earnings - 06 Nov, 2024
Gland Pharma's stock rose on positive brokerage outlooks, despite weak Q2 results. Analysts note potential for gradual progress in biologics CDMO, but caution over earnings performance and margin pressures.
Gland Pharma Stock Surges After Q2 Earnings Report - 05 Nov, 2024
Gland Pharma's Q2 results show a mixed performance with a decline in net profit but a rise in revenue. The stock surged over 13%, indicating brokerages' optimism about recovery. Analysts believe the worst may be behind the company, leading to significant gains in stock price.
Gland Pharma Reports Decline in Q2 Profit - 04 Nov, 2024
Gland Pharma reported a 16% decline in net profit for Q2 FY25, attributed to lower sales in Europe and production issues. Revenue grew 2%, but shares fell 2.15%. The company remains optimistic about future growth and strategic partnerships.
Gland Pharma Appoints New CEO for 2025 - 18 Oct, 2024
Gland Pharma has appointed Shyamakant Giri as its new CEO, effective January 15, 2025. Giri, currently with Amneal Pharmaceuticals, will lead the company's growth, while Srinivas Sadu continues as executive chairman.
Insights on Gland Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 143.76 Cr → 163.53 Cr (in ₹), with an average increase of 12.1% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 30.53% to 32.83% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 1.45K Cr → 1.46K Cr (in ₹), with an average increase of 0.8% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.83% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 67.8% return, outperforming this stock by 56.7%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.8% return, outperforming this stock by 173.1%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 6.88% to 4.47% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 years, GLAND stock has moved down by -47.3%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.45% to 8.32% in Sep 2024 quarter
Gland Pharma Ltd Financials
Index Inclusions
Gland Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.83% | 0.00 | |
| Foreign Institutions | 4.47% | ||
| Mutual Funds | 32.83% | 7.53 | |
| Retail Investors | 8.32% | ||
| Others | 2.54% | 10.52 |
Gland Pharma Ltd Key Indicators
Gland Pharma Ltd Valuation
Gland Pharma Ltd in the last 5 years
Lowest (18.84x)
May 22, 2023
Today (43.30x)
November 11, 2024
Industry (56.74x)
November 11, 2024
Highest (67.14x)
August 12, 2021
Gland Pharma Ltd Earnings and Dividends
Gland Pharma Ltd Earnings Results
Gland Pharma Ltd’s net profit fell -15.74% since last year same period to ₹163.53Cr in the Q2 2024-2025. On a quarterly growth basis, Gland Pharma Ltd has generated 13.75% jump in its net profits since last 3-months.
Read More about Earnings ResultsGland Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Gland Pharma Ltd has declared dividend of ₹20 - translating a dividend yield of 1.13%.
Read More about Dividends
Gland Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Gland Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Gland Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Gland Pharma Ltd shares.
Gland Pharma Ltd (GLAND) share price today is ₹1764.55
Gland Pharma Ltd is listed on NSE
Gland Pharma Ltd is listed on BSE
- Today’s highest price of Gland Pharma Ltd is ₹1831.9.
- Today’s lowest price of Gland Pharma Ltd is ₹1750.
PE Ratio of Gland Pharma Ltd is 43.3
PE ratio = Gland Pharma Ltd Market price per share / Gland Pharma Ltd Earnings per share
Today’s traded volume of Gland Pharma Ltd(GLAND) is 87.56K.
Today’s market capitalisation of Gland Pharma Ltd(GLAND) is ₹29953.51Cr.
| Gland Pharma Ltd(GLAND | Price |
|---|---|
52 Week High | ₹2220.95 |
52 Week Low | ₹1585.7 |
Gland Pharma Ltd(GLAND) share price is ₹1764.55. It is down -20.55% from its 52 Week High price of ₹2220.95
Gland Pharma Ltd(GLAND) share price is ₹1764.55. It is up 11.28% from its 52 Week Low price of ₹1585.7
| Gland Pharma Ltd(GLAND | Returns |
|---|---|
1 Day Returns | -53.55% |
1 Month Returns | 8.15% |
3 Month Returns | -10.79% |
1 Year Returns | 11.07% |